Study: Cancer vaccine promising results world and science

None of the first eight vaccinated patients relapsed.Eluar Berdigao

Posted on 07/07/2022 09:38 | Updated on 07/07/2022 09:41

A customized cancer vaccine made from a patient’s DNA has achieved hopeful preliminary results in clinical trials at Clatterbridge Cancer Centre, one of England’s leading medical study centres. The pilot study is still preliminary, with only a small number of participants, and the data has not been published in a scientific journal yet.

But for experts, this type of treatment offers hope for new treatments. They claim that more testing with the treatment is still needed to understand the product’s efficacy.

Cancer vaccine has been applied as a complementary treatment for patients with head and neck diseases – those affecting the mouth, pharynx (throat), larynx and nasal cavity as well as the skin, salivary glands, blood vessels, muscles and nerves in the area, as well as the thyroid gland.

None of the first eight vaccinated patients relapsed. On the other hand, the cancer returned in two of the eight patients who had already been vaccinated. The results were presented at the American Congress of Clinical Oncology in June.

For specialists analyzing the first results of research, although the study numbers are small, they have not been published in scientific journals, the customization brought by this technology opens a new perspective in cancer treatment.

Christian Ottenmaier, MD, consultant medical oncologist and director of research at Clatterbridge Cancer Center, has shown a measure of caution, but optimism for the next phases of the research. Right,” he said